An immunohistochemical analysis of ras oncogene expression in epithelial neoplasms of the colon.
Colonic epithelial tumors (101) including villoglandular adenomas, carcinomas in situ, adenocarcinomas, and neuroendocrine (NE) carcinomas were studied immunohistochemically with monoclonal antibodies (MoAb) RAP-5 and RAS-10 recognizing altered and unaltered ras oncogene products. In addition, 20 samples from multiple polyposis including adenomas with and without dysplasia, carcinomas in situ, and invasive carcinomas were studied. Using immunostaining techniques, normal mucosa was weakly stained, whereas the mucosa in the vicinity of tumors or inflammation showed enhanced staining. More tumors stained intensely with MoAb RAP-5 than with MoAb RAS-10. With MoAb RAP-5, most benign and malignant tumors showed enhanced staining. No significant differences in staining were noted in relation to superficial versus deeply invasive carcinomas or clinical staging. Immunostaining was also noted in some metastases. No significant differences in enhanced staining were found in carcinomas. Interestingly, the most extensive and enhanced immunostaining was noted in the villoglandular adenomas, dysplastic adenomas, and carcinomas in situ. The authors conclude that (1) ras protein expression is detectable in most benign, borderline, and malignant epithelial tumors of the colon as determined with MoAb RAP-5 and RAS-10, whereas enhanced expression is more often detected with RAP-5; (2) enhanced ras product expression in colon carcinomas does not seem to correlate with advanced tumor stages or with exocrine, NE, or phenotypically mixed tumors; and (3) the finding of the most intensely enhanced ras products expression in villoglandular polyps and carcinomas in situ suggests a possibly significant role for the oncogene in the early phases of transformation.
Jansson
D S
DS
Department of Pathology, Rush Medical College, Chicago, Illinois 60612.
Radosevich
J A
JA
Carney
W P
WP
Rosen
S T
ST
Schlom
J
J
Staren
E D
ED
Hyser
M J
MJ
Gould
V E
VE
D000230:Adenocarcinoma / Q000032:analysis / Q000235:genetics; D000236:Adenoma / Q000032:analysis / Q000235:genetics; D000911:Antibodies, Monoclonal; D002277:Carcinoma / Q000032:analysis / Q000235:genetics; D002278:Carcinoma in Situ / Q000032:analysis / Q000235:genetics; D003110:Colonic Neoplasms / Q000032:analysis / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic; D011905:Genes, ras; D006801:Humans; D007158:Immunologic Techniques
D000911:Antibodies, Monoclonal